208 related articles for article (PubMed ID: 35054884)
1. Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer.
Yun HJ; Kim M; Kim SY; Fang S; Kim Y; Chang HS; Chang HJ; Park KC
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054884
[TBL] [Abstract][Full Text] [Related]
2. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
3. Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
Kim SM; Park K; Lim JH; Yun HJ; Kim SY; Choi KH; Kim CW; Lee JH; Weicker R; Pan CH; Park KC
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142303
[TBL] [Abstract][Full Text] [Related]
4. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Iesato A; Li S; Roti G; Hacker MR; Fischer AH; Nucera C
J Clin Endocrinol Metab; 2021 Nov; 106(12):3569-3590. PubMed ID: 34302727
[TBL] [Abstract][Full Text] [Related]
7. Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma.
Chang HS; Kim Y; Lee SY; Yun HJ; Chang HJ; Park KC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108231
[TBL] [Abstract][Full Text] [Related]
8. Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.
Kim Y; Yun HJ; Choi KH; Kim CW; Lee JH; Weicker R; Kim SM; Park KC
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003602
[TBL] [Abstract][Full Text] [Related]
9. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
Elia G; Ferrari SM; Ragusa F; Paparo SR; Mazzi V; Ulisse S; Benvenga S; Antonelli A; Fallahi P
Expert Opin Pharmacother; 2022 Apr; 23(5):599-610. PubMed ID: 35038965
[TBL] [Abstract][Full Text] [Related]
10. p53-dependent apoptosis is essential for the antitumor effect of paclitaxel response to DNA damage in papillary thyroid carcinoma.
Wu W; Wei T; Li Z; Zhu J
Int J Med Sci; 2021; 18(14):3197-3205. PubMed ID: 34400889
[TBL] [Abstract][Full Text] [Related]
11. Control of Lung Metastases and Colon Polyposis with Lenvatinib Therapy in a Patient with Cribriform-Morular Variant of Papillary Thyroid Carcinoma and an
Ito Y; Ishikawa H; Kihara M; Hirokawa M; Kiyota N; Kasahara T; Miyauchi A
Thyroid; 2019 Oct; 29(10):1511-1517. PubMed ID: 31317827
[No Abstract] [Full Text] [Related]
12. Noncoding RNAs in Papillary Thyroid Cancer: Interaction with Cancer-Associated Fibroblasts (CAFs) in the Tumor Microenvironment (TME) and Regulators of Differentiation and Lymph Node Metastasis.
Dadafarin S; Carnazza M; Islam HK; Moscatello A; Tiwari RK; Geliebter J
Adv Exp Med Biol; 2021; 1350():145-155. PubMed ID: 34888848
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
[No Abstract] [Full Text] [Related]
16. Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer.
Kim SM; Kim SY; Park CS; Chang HS; Park KC
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32075109
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.
Soares P; Lima J; Preto A; Castro P; Vinagre J; Celestino R; Couto JP; Prazeres H; Eloy C; Máximo V; Sobrinho-Simões M
Curr Genomics; 2011 Dec; 12(8):609-17. PubMed ID: 22654560
[TBL] [Abstract][Full Text] [Related]
19. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
20. Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Hussain AR; Bu R; Ahmed M; Jehan Z; Beg S; Al-Sobhi S; Al-Dayel F; Siraj AK; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2015 Jul; 100(7):E974-85. PubMed ID: 25974735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
